RE:RE:RE:RE:RE:RE:Questions for the company.Domino55 wrote: Hm. I disagree,
When your FDA approvals are valued at 5 cents per, your late stage PMX confirmatory trial at NOTHING, the share price down 65% in 6 months and down 50% YoY you need to explain that to your shareholders.
We are owed an explanation of how 12 months of development has gotten the SP to where it is.
Another gold star Dom
If the underlying assets don't change
And any given stock's value (presumably) is fundamentally represented by all future cash flows (for at least the next 20 years) discounted to present day
Should a delay of 6 -9 months (of the start of revenues) really have a material impact (e.g 2/3 loss of MC) on the value of said given stock?
Unless the value is not truly reflected in the SP to begin with (maybe because no one has heard of it)
And it trades on a very illiquid market with little to no news flow to the most improtant market (where the lions share of the future products will be sold)
And what about, most important of all ...
...the likely (possible at least) increasing amount of future revenues if PMX can be used to save the lives of serious Covid patients (800,000 americans have died so far, and > 30,000 Cdns) a very high percentage of which develop endotoxemia (apparently based on current published Studies, Ronco and Kellum)
Does this last fact potentially doube future revenues? Triple them?
So agian, why does the SP fall in the face of a potentially
much much much bigger opportunity ?
That's the number 1 question to be answered ! And the only one I care about.
MM